New drug cocktail shows promise for Hard-to-Treat myeloma
NCT ID NCT04850599
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in adults with multiple myeloma that has come back or is not responding to prior treatments. The goal is to see if this mix can shrink or control the cancer. The trial enrolled 5 participants and is no longer recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood cancer transplant study tests safer GVHD prevention
- New hope for hard-to-treat myeloma: three-drug combo enters phase 2 trial
- Stem cell transplant study seeks best way to prevent immune attack
- New immune cell therapy takes on Hard-to-Treat myeloma
- New combo tackles resistant myeloma in early trial
- New transplant recipe may tame Graft-Versus-Host disease in blood cancer patients